Richard E. Reitz, MD
Dr. Medical Director, Endocrinology San Juan Capistrano,CA USA. More about professional consults.
Molecular diagnostic panel for thyroid cancer disease management
Dr. Reitz describes the findings during an oral presentation at the June 4, 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). View the abstract: Molecular diagnostic panel for thyroid cancer disease management.
NEW MOLECULAR TEST PANEL FOR ENHANCED THYROID CANCER DETECTION
The test is believed to be the most comprehensive panel clinically available to identify mutations associated with four gene markers indicated by the American Thyroid Association for the clinical management of indeterminate thyroid biopsies.
COMPREHENSIVE THYROID CANCER TESTING
About 5% to 15% of thyroid nodules detected in the United States are malignant.1 Accurate diagnosis is essential to avoid unnecessary thyroid surgery for benign disease and to select the most appropriate treatment option for cancerous nodules.
Online Presentation: Advances in Thyroid Cancer Testing
Drs. Richard Reitz and Frederic Waldman, Medical Directors, Quest Diagnostics Nichols Institute, discuss recent developments in the field of thyroid cancer, in particular the significance of genetic mutations in thyroid cancer.
Educating Patients
As part of our service, you can access patient education materials to address common patient questions about diseases and tests. Direct your patients to our Diagnostic Testing A-Z page for information about Thyroid cancer diagnostic testing.
Quest Diagnostics Interpretive Guides
Find information relating to test selection, utilization, and interpretation. All information is based on peer-reviewed publications, practice guidelines, or other reputable sources.